ReviewActa bio-medica : Atenei Parmensis2020
Treatments for COVID-19: emerging drugs against the coronavirus.
Review in Acta bio-medica : Atenei Parmensis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Properties of Yoghurt Fortified in Lactoferrin with Effect of Storage Time.Animals : an open access journal from MDPI · 2023Article
- Lactoferrin-The Health-Promoting Properties and Contemporary Application with Genetic Aspects.Foods (Basel, Switzerland) · 2022Review
- COVID-19 and the Pancreas: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Untargeted plasma metabolomic fingerprinting highlights several biomarkers for the diagnosis and prognosis of coronavirus disease 19.Frontiers in medicine · 2022Article
- Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments.International journal of environmental research and public health · 2021Review
- A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.International journal of biological macromolecules · 2021Review
- COVID-19 … What are drugs and strategies now?Acta bio-medica : Atenei Parmensis · 2021Article
- Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.Journal of the American Academy of Dermatology · 2020Review
- Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.Chemico-biological interactions · 2020Review
- Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach.JMIR medical informatics · 2020Article
- How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.Acta bio-medica : Atenei Parmensis · 2020Review
- Treatments for COVID-19: emerging drugs against the coronavirus - reply.Acta bio-medica : Atenei Parmensis · 2020Article
- Treatments for COVID-19: emerging drugs against the coronavirus.Acta bio-medica : Atenei Parmensis · 2020Article
- What we have learned from the COVID-19 pandemic: Time to think outside the box, maybe far outside.Clinics in dermatologyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus disease 19 (COVID-19) outbreak has been recognized as a global threat to public health. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and no effective therapies currently exist against this novel viral agent. Along with extensive public health measures, an unprecedented global effort in identifying effective drugs for the treatment is being implemented. Potential drug targets are emerging as the result of a fast-evolving understanding of SARS-CoV-2 virology, host response to the infection, and clinical course of the disease. This brief review focuses on the latest and most promising pharmacological treatments against COVID-19 currently under investigation and discuss their potential use based on either documented efficacy in similar viral infections, or their activity against inflammatory syndromes. Ongoing clinical trials are also emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.